Lambert Eaton Myasthenic Syndrome
0
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Colorado TherapeuticsCO - Louisville
1 program3, 4-DiaminopyridineN/A1 trial
Active Trials
NCT01825395Approved For Marketing
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Catalyst PharmaceuticalsAmifampridine Phosphate
Clinical Trials (2)
Total enrollment: 38 patients across 2 trials
A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS)
Start: Jun 2011Est. completion: Jul 201638 patients
Phase 3Completed
Use of 3,4-Diaminopyridine in the Treatment of Lambert-Eaton Syndrome
N/AApproved For Marketing
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.